A Clinical Trial to Demonstrate the Efficacy of Cangrelor
Launched by THE MEDICINES COMPANY · Mar 20, 2006
Trial Information
Current as of May 23, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • INCLUSION CRITERIA
- To be included in this study, subjects must meet the following criteria:
- • Angiography demonstrating atherosclerosis amenable to treatment by percutaneous coronary intervention (PCI) with or without stent implantation and diagnosis of Acute Coronary Syndrome (ACS) by elevated cardiac markers or ischemic chest discomfort w/electrocardiogram changes + age \> 65 or diabetes or ST-elevation MI.
- • EXCLUSION CRITERIA
- Subjects will be excluded from the study if they present with any of the following:
- • 1. Not a candidate for PCI
- • 2. Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (\<1 month) trauma or major surgery (including by-pass surgery); currently receiving warfarin, active bleeding
- • 3. Impaired hemostasis: known International Normalized Ratio (INR) \>1.5 at screening; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count \<100,000/µL), or history of thrombocytopenia or neutropenia associated with clopidogrel
- • 4. Severe hypertension not adequately controlled by antihypertensive therapy at the time of randomization
- • 5. Receipt of fibrinolytic therapy in the 12 hours preceding randomization
- • 6. Receipt of clopidogrel dose exceeding maintenance dose (ie, \>75 mg) at any time in the 5 days preceding randomization
- • 7. Inability to swallow study capsules
- • 8. Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours \[applicable to unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) patients\]
- • Subjects excluded for any of the above reasons may be re-screened for participation at any time if the exclusion characteristic has changed.
About The Medicines Company
The Medicines Company, a global pharmaceutical organization, is dedicated to advancing innovative therapeutic solutions to address urgent medical needs. Focused on developing and commercializing novel medicines, the company specializes in critical care and cardiovascular therapies. With a commitment to rigorous scientific research and clinical excellence, The Medicines Company aims to improve patient outcomes through its robust pipeline of products and collaborative partnerships within the healthcare community. Through its dedication to innovation and patient-centric approaches, the company strives to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Deepak L. Bhatt, MD
Principal Investigator
The Cleveland Clinic
Robert A. Harrington, MD
Principal Investigator
Duke University Medical Center and Duke Clinical Research Institute
Simona Skerjanec, PharmD
Study Director
The Medicines Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials